Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenyu Ningshen Tablets of Guangdong Siji Pharmaceutical Co., Ltd was approved for marketing by China NMPA.

A randomized, double-blind, placebo-controlled multicenter clinical trial was conducted on this medicine, and the results showed that in regard of the primary efficacy endpoints (HAMD-17 score reduction rate ≥ 50% is recognized as effective) compared between groups, the efficacy of the treatment group was better than that of the placebo group.

This medicine which replenishing Qi and nourishing Yin, tranquilizing Shen and alleviating depression, is indicated to treat mild and moderate depression with TCM syndrome differentiation of Qi and Yin deficiency. The marketing of this drug provides another treatment option for patients with depression.